
## Lubor Golan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7997200/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors. Annals of Internal Medicine, 1999, 131, 660.	2.0	126
2	Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). Journal of Inherited Metabolic Disease, 2014, 37, 455-460.	1.7	47
3	Replacement of α-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 651-665.	1.4	29
4	The coincidence of IgA nephropathy and Fabry disease. BMC Nephrology, 2013, 14, 6.	0.8	15
5	Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. Drug Design, Development and Therapy, 2015, 9, 3435.	2.0	15
6	Association between tyrosine hydroxylase polymorphisms and left ventricular structure in young normotensive men. British Journal of Biomedical Science, 2002, 59, 90-94.	1.2	9
7	Fabry disease - Vascular manifestations. Vasa - European Journal of Vascular Medicine, 2010, 39, 123-131.	0.6	9
8	The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment. Vasa - European Journal of Vascular Medicine, 2009, 38, 238-244.	0.6	7
9	Pitfalls of Xâ€chromosome inactivation testing in females with Fabry disease. American Journal of Medical Genetics, Part A, 2022, 188, 1979-1989.	0.7	5
10	Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease. PLoS ONE, 2016, 11, e0166290.	1.1	4
11	Serum Bilirubin Levels and Promoter Variations in <i>HMOX1</i> and <i>UGT1A1</i> Genes in Patients with Fabry Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-6.	1.9	3
12	Normative reference ranges for echocardiographic chamber dimensions in a healthy Central European population: results from the Czech post-MONICA survey. Cardiovascular Ultrasound, 2019, 17, 22.	0.5	3
13	Migalastat in the treatment of Fabry disease. Interni Medicina Pro Praxi, 2017, 19, 167-170.	0.0	1
14	Fabry disease. Interni Medicina Pro Praxi, 2018, 20, 10-13.	0.0	0
15	Cardiologic evaluation in Fabry disease. Intervencni A Akutni Kardiologie, 2018, 17, 67-70.	0.0	Ο